FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955681008> ?p ?o ?g. }

• W2955681008 endingPage "148" @default.
• W2955681008 startingPage "133" @default.
• W2955681008 abstract "Zoledronic acid (ZOL), a nitrogen bisphosphonate (N-BP), is currently used to treat and control pediatric osteolytic diseases. Variations in the intensity of the effects and side effects of N-BPs have been reported with no clear explanations regarding their origins. We wonder if such variations could be associated with different levels of RANKL signaling activity in growing bone during and after the treatment with N-BPs. To answer this question, ZOL was injected into neonate C57BL/6J mice with different genetically-determined RANKL signaling activity levels (Opg+/+RankTg−, Opg+/+RankTg+, Opg+/−RankTg−, Opg+/−RankTg+, Opg−/−RankTg− and Opg−/−RankTg+ mice) following a protocol (4 injections from post-natal day 1 to 7 at the dose of 50 μg/kg) that mimics those used in onco-pediatric patients. At the end of pediatric growth (1 and half months) and at an adult age (10 months), the bone morphometric and mineral parameters were measured using μCT in the tibia and skull for the different mice. A histologic analysis of the dental and periodontal tissues was also performed. At the end of pediatric growth, a delay in long bone and skull bone growth, a blockage of tooth eruption, some molar root alterations and a neoplasia-like structure associated with incisor development were found. Interestingly, the magnitude of these side effects was reduced by Opg deficiency (Opg−/−) but increased by Rank overexpression (RankTg). Analysis of the skeletal phenotype at ten months confirmed respectively the beneficial and harmful effects of Opg deficiency and Rank overexpression. These results validated the hypothesis that the RANKL signaling activity level in the bone microenvironment is implicated in the modulation of the response to ZOL. Further studies will be necessary to understand the underlying molecular mechanisms, which will help decipher the variability in the effects of N-BPs reported in the human population. The present study establishes that in mice the RANKL signaling activity level is a major modulator of the effects and side-effects of bisphosphonates on the individual skeleton during growth. However, the modulatory actions are dependent on the ways in which this level of activity is increased. A decrease in OPG expression is beneficial to the skeletal phenotype observed at the end of growth, while RANK overexpression deteriorates it. Far removed from pediatric treatment, in adults, the skeletal phenotypes initially observed at the end of growth for the different levels of RANKL signaling activity were maintained, although significant improvement was associated only with reductions in OPG expression." @default.
• W2955681008 created "2019-07-12" @default.
• W2955681008 creator A5005648937 @default.
• W2955681008 creator A5019382716 @default.
• W2955681008 creator A5040630567 @default.
• W2955681008 creator A5049291969 @default.
• W2955681008 creator A5065332545 @default.
• W2955681008 creator A5077898438 @default.
• W2955681008 creator A5079593036 @default.
• W2955681008 date "2019-10-01" @default.
• W2955681008 modified "2023-10-16" @default.
• W2955681008 title "Genetically-achieved disturbances to the expression levels of TNFSF11 receptors modulate the effects of zoledronic acid on growing mouse skeletons" @default.
• W2955681008 cites W1494556649 @default.
• W2955681008 cites W1549053710 @default.
• W2955681008 cites W1926649699 @default.
• W2955681008 cites W1975953388 @default.
• W2955681008 cites W1977753585 @default.
• W2955681008 cites W1989877176 @default.
• W2955681008 cites W1991753885 @default.
• W2955681008 cites W1992301360 @default.
• W2955681008 cites W1993006174 @default.
• W2955681008 cites W1997328782 @default.
• W2955681008 cites W1999985403 @default.
• W2955681008 cites W2003897456 @default.
• W2955681008 cites W2006543639 @default.
• W2955681008 cites W2009713306 @default.
• W2955681008 cites W2019076654 @default.
• W2955681008 cites W2025112163 @default.
• W2955681008 cites W2025672294 @default.
• W2955681008 cites W2030586275 @default.
• W2955681008 cites W2031595229 @default.
• W2955681008 cites W2033872292 @default.
• W2955681008 cites W2037212570 @default.
• W2955681008 cites W2037927763 @default.
• W2955681008 cites W2043377701 @default.
• W2955681008 cites W2045995534 @default.
• W2955681008 cites W2059695009 @default.
• W2955681008 cites W2064274065 @default.
• W2955681008 cites W2068709785 @default.
• W2955681008 cites W2071310237 @default.
• W2955681008 cites W2077855619 @default.
• W2955681008 cites W2079173609 @default.
• W2955681008 cites W2079555209 @default.
• W2955681008 cites W2089354715 @default.
• W2955681008 cites W2093354768 @default.
• W2955681008 cites W2095226573 @default.
• W2955681008 cites W2097119154 @default.
• W2955681008 cites W2111779899 @default.
• W2955681008 cites W2125060453 @default.
• W2955681008 cites W2147919094 @default.
• W2955681008 cites W2158332324 @default.
• W2955681008 cites W2168451480 @default.
• W2955681008 cites W2215290758 @default.
• W2955681008 cites W2277706272 @default.
• W2955681008 cites W2330722106 @default.
• W2955681008 cites W2344880307 @default.
• W2955681008 cites W2404285912 @default.
• W2955681008 cites W2486620161 @default.
• W2955681008 cites W2520201755 @default.
• W2955681008 cites W2523617446 @default.
• W2955681008 cites W2530760833 @default.
• W2955681008 cites W2535925391 @default.
• W2955681008 cites W2560464781 @default.
• W2955681008 cites W2571353700 @default.
• W2955681008 cites W2581501541 @default.
• W2955681008 cites W2593115970 @default.
• W2955681008 cites W2619460931 @default.
• W2955681008 cites W2776967789 @default.
• W2955681008 cites W2782861663 @default.
• W2955681008 cites W2789781781 @default.
• W2955681008 cites W2793456055 @default.
• W2955681008 cites W2798241187 @default.
• W2955681008 cites W2900031920 @default.
• W2955681008 doi "https://doi.org/10.1016/j.bcp.2019.06.027" @default.
• W2955681008 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31260659" @default.
• W2955681008 hasPublicationYear "2019" @default.
• W2955681008 type Work @default.
• W2955681008 sameAs 2955681008 @default.
• W2955681008 citedByCount "7" @default.
• W2955681008 countsByYear W29556810082020 @default.
• W2955681008 countsByYear W29556810082021 @default.
• W2955681008 countsByYear W29556810082022 @default.
• W2955681008 countsByYear W29556810082023 @default.
• W2955681008 crossrefType "journal-article" @default.
• W2955681008 hasAuthorship W2955681008A5005648937 @default.
• W2955681008 hasAuthorship W2955681008A5019382716 @default.
• W2955681008 hasAuthorship W2955681008A5040630567 @default.
• W2955681008 hasAuthorship W2955681008A5049291969 @default.
• W2955681008 hasAuthorship W2955681008A5065332545 @default.
• W2955681008 hasAuthorship W2955681008A5077898438 @default.
• W2955681008 hasAuthorship W2955681008A5079593036 @default.
• W2955681008 hasBestOaLocation W29556810081 @default.
• W2955681008 hasConcept C105702510 @default.
• W2955681008 hasConcept C126322002 @default.
• W2955681008 hasConcept C134018914 @default.
• W2955681008 hasConcept C170493617 @default.
• W2955681008 hasConcept C2776326535 @default.
• W2955681008 hasConcept C2776541429 @default.

• next